About Intellectual Property Issues

This information is for the customers of Olympus “Micro laser scanning microscope” and “In vivo observation system”.

“Micro laser scanning microscope system“ Notice: The “Micro laser scanning microscope system“ has many potential applications. Certain of these applications and materials used with them may require licensing under patents held by third parties. For example, AntiCancer, Inc. and Xenogen Corporation each own several patents in the field of imaging cells genetically engineered to produce light emitting compounds. Olympus has obtained a license from Anti-Cancer, such that non-profit entities purchasing the “Micro laser scanning microscope system“ are licensed under AntiCancer U.S. Patent Nos. 6,232,523, 6,649,159, 6,235,968, 6,251,384 and 6,759,038 for noncommercial uses. Olympus' sale or other transfer of the “Micro laser scanning microscope system“ does not convey any additional rights or licenses under third party patents. It is suggested that users of the “Micro laser scanning microscope system“ consult with counsel to determine whether licensing of additional third party patents is required.

“In vivo observation system” Notice: The “In vivo observation system” has many potential applications. Certain of these applications and materials used with them may require licensing under patents held by third parties. For example, AntiCancer, Inc. “In vivo observation system”and Xenogen Corporation each own several patents in the field of imaging cells genetically engineered to produce light emitting compounds. Olympus has obtained a license from Anti-Cancer, such that non-profit entities purchasing the “In vivo observation system” are licensed under AntiCancer U.S. Patent Nos. 6,232,523, 6,649,159, 6,235,968, 6,251,384 and 6,759,038 for noncommercial uses. Olympus' sale or other transfer of the “In vivo observation system” does not convey any additional rights or licenses under third party patents. It is suggested that users of the “In vivo observation system” consult with #1072806 v2106149-56721 counsel to determine whether licensing of additional third party patents is required.